Abstract
Respiratory syncytial virus (RSV) causes severe respiratory disease in calves and human infants. In response to outbreaks, formalin inactivated (FI)-RSV vaccines were developed and found to exacerbate disease following a live RSV infection. We have reproduced vaccination induced disease enhancement in calves and screened various antibody isotypes in bronchoalveolar lavage fluid (BALF) from two studies: one with disease enhancement and another where moderate protection resulted from FI-bovine RSV (BRSV) vaccination. Semi-protected vaccinated calves produced BRSV-specific BALF IgG1, but not IgA and IgG2 prior to infection; whereas, calves with enhanced disease failed to develop BRSV-specific IgG1 in BALF. Ultimately, the formulation and delivery of RSV vaccines influences protective antibody levels in respiratory secretions.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antibodies, Viral / biosynthesis*
-
Antibodies, Viral / blood
-
Antibody Formation
-
Bronchoalveolar Lavage*
-
Cattle
-
Cattle Diseases / immunology
-
Cattle Diseases / metabolism
-
Cattle Diseases / prevention & control*
-
Formaldehyde / pharmacology*
-
Respiratory Syncytial Virus Infections / metabolism
-
Respiratory Syncytial Virus Infections / prevention & control
-
Respiratory Syncytial Virus Infections / veterinary*
-
Respiratory Syncytial Virus Vaccines / administration & dosage
-
Respiratory Syncytial Virus Vaccines / immunology
-
Respiratory Syncytial Virus, Bovine / drug effects*
-
Respiratory Syncytial Virus, Bovine / immunology
-
Treatment Outcome
-
Vaccines, Attenuated / administration & dosage*
-
Vaccines, Attenuated / immunology
Substances
-
Antibodies, Viral
-
Respiratory Syncytial Virus Vaccines
-
Vaccines, Attenuated
-
Formaldehyde